Effects of two and three vaccinations with the bivalent HPV vaccine on the prevalence and load of HPV in clearing and persistent infections in young women
- 29 March 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Abstract
Human papillomavirus viral load (HPV VL) is associated with persistence, which increases cervical cancer risk. The bivalent vaccine protects against oncogenic HPV16/18 and cross-protects against several non-vaccine types. We examined the effect of two-dose (2D) and three-dose (3D) vaccination on HPV prevalence and viral load in clearing (CIs) and persistent infections (PIs), 6y and 12y post-vaccination, respectively. Vaginal swabs collected from HPV Among Vaccinated And Non-vaccinated Adolescents (HAVANA, 3D-eligible) and HAVANA-2 (2D-eligble) participants were genotyped for HPV with the SPF10-DEIA-LiPA25. HPV VL was measured with type-specific qPCRs. HPV16, 18, 31, 33 and 45 CI and/or PI prevalence and HPV16, 18, and 31 VLs in CIs were significantly reduced in 3D vaccinated women compared to unvaccinated women. Except for HPV11 and HPV59 CIs, no significant VL differences were observed among vaccinated women, ≤6y and >6y post-vaccination. Infection numbers were low in 2D-eligible women, with no HPV16 and 18 in vaccinated women. No VL differences for the remaining types were found. 3D vaccination reduces HPV prevalence in CIs and PIs and decreases HPV VLs in CIs, 12y post-vaccination for vaccine and several non-vaccine types. 2D-eligible women had low infection numbers, with no HPV16/18 among vaccinated women.Keywords
This publication has 31 references indexed in Scilit:
- Correlation between viral load, multiplicity of infection, and persistence of HPV16 and HPV18 infection in a Dutch cohort of young womenJournal of Clinical Virology, 2016
- Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized studyHuman Vaccines & Immunotherapeutics, 2015
- The original SPF10 LiPA25 algorithm is more sensitive and suitable for epidemiologic HPV research than the SPF10 INNO-LiPA ExtraJournal of Virological Methods, 2015
- Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected ObservationThe Journal of Infectious Diseases, 2013
- Human papillomavirus genome variantsVirology, 2013
- Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccinationCancer Epidemiology, 2012
- Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialThe Lancet Oncology, 2012
- AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive ImmunityThe Journal of Immunology, 2009
- Comparison of Two PCR-Based Human Papillomavirus Genotyping MethodsJournal of Clinical Microbiology, 2008
- Multiplex, Quantitative, Real-Time PCR Assay for Cytomegalovirus and Human DNAJournal of Clinical Microbiology, 2002